KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug development.Contemp Clin TrialsPMID 35803494无 PMCID2022-Aug0.80The record describes a methodological paper about statistical design (2-in-1 design) for oncology drug development, not a report of an original randomized clinical trial's efficacy results. It lacks a specific drug intervention, does not report time-to-event efficacy data, and is not a primary result publication.待处理
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.Lancet OncolPMID 35810754无 PMCID2022-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.Lancet OncolPMID 35835135无 PMCID2022-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.Lancet NeurolPMID 35841908无 PMCID2022-Aug0.98未发现恶性肿瘤人群证据。待处理
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.ESMO OpenPMID 35843080PMC94344082022-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.Acta OncolPMID 35847998无 PMCID2022-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS DrugsPMID 35896943PMC93281822022-Aug0.98未发现恶性肿瘤人群证据。待处理
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration.Indian J OphthalmolPMID 35918962PMC96727152022-Aug0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.NEJM EvidPMID 38319878无 PMCID2022-Aug0.98未发现恶性肿瘤人群证据。待处理
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.NEJM EvidPMID 38319892无 PMCID2022-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.NEJM EvidPMID 38319896无 PMCID2022-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.VaccinePMID 35738968PMC92124352022-Jul-300.98未发现恶性肿瘤人群证据。待处理
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 35908570无 PMCID2022-Jul-300.85The study is a randomized, double-blind, phase 3 trial of upadacitinib in axial spondyloarthritis, meeting criteria for oncology (rheumatic disease is sometimes classified under oncology-related conditions, but the primary endpoint is a categorical response, not a time-to-event outcome). The primary efficacy endpoint is the proportion of patients achieving ASAS40 response at week 14, which is a binary outcome, not a time-to-event endpoint such as overall survival, progression-free survival, or any other survival metric analyzed via Kaplan-Meier or hazard ratio. Therefore, it does not meet the inclusion criterion for a time-to-event efficacy endpoint.待处理
Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).Radiat OncolPMID 35906623PMC93385572022-Jul-290.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.BMC Pharmacol ToxicolPMID 35902898PMC93360692022-Jul-280.90The study is a Phase III randomized trial with a drug intervention (trastuzumab biosimilar) in human oncology (breast cancer). However, the primary endpoint is pathologic complete response (pCR), which is a binary endpoint, not a time-to-event endpoint. The secondary endpoints include ORR and BCS, which are also not time-to-event. No time-to-event outcomes (OS, PFS, DFS, etc.), Kaplan-Meier curves, or hazard ratios are reported in the abstract.待处理
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.Blood AdvPMID 35413116PMC93275342022-Jul-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.JAMAPMID 35881122PMC93275732022-Jul-260.98未发现恶性肿瘤人群证据。待处理
Postoperative Diet with an Oligomeric Hyperproteic Normocaloric Supplement versus a Supplement with Immunonutrients in Colorectal Cancer Surgery: Results of a Multicenter, Double-Blind, Randomized Clinical Trial.NutrientsPMID 35893914PMC93312232022-Jul-260.85The study is a randomized, phase III trial in colorectal cancer with an original primary result, but it compares two dietary supplements (nutritional interventions) without a drug-containing arm and reports complications/readmissions as primary/secondary outcomes, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR.待处理
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.LancetPMID 35871814无 PMCID2022-Jul-230.98未发现恶性肿瘤人群证据。待处理
Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J MedPMID 35658024无 PMCID2022-Jul-210.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J MedPMID 35857659无 PMCID2022-Jul-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.Cardiovasc ResPMID 34358298PMC93028852022-Jul-200.95The study is not oncology (focus is atrial fibrillation and cardiovascular death, not human malignant neoplasm). Therefore, it does not meet the core oncology eligibility requirement.待处理
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.J Clin OncolPMID 35333599PMC92872812022-Jul-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.J Clin OncolPMID 35427190无 PMCID2022-Jul-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.JAMAPMID 35852527PMC92971192022-Jul-190.98未发现恶性肿瘤人群证据。待处理
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.HIV Res Clin PractPMID 35938597PMC100293592022-Jul-190.98未发现恶性肿瘤人群证据。待处理
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.Gut LiverPMID 35791797PMC92898272022-Jul-150.98未发现恶性肿瘤人群证据。待处理
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.N Engl J MedPMID 35660812PMC100408992022-Jul-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.Prog Neuropsychopharmacol Biol PsychiatryPMID 35304155无 PMCID2022-Jul-130.98未发现恶性肿瘤人群证据。待处理
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.Nat CommunPMID 35821019PMC92767252022-Jul-120.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J MedPMID 35665782PMC105616522022-Jul-070.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.Diabetes CarePMID 35671039PMC92742252022-Jul-070.98未发现恶性肿瘤人群证据。待处理
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.BMJ OpenPMID 35798516PMC92639272022-Jul-070.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.Rheumatology (Oxford)PMID 34730795PMC92585422022-Jul-060.98未发现恶性肿瘤人群证据。待处理
Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.Rheumatology (Oxford)PMID 34791107PMC92585902022-Jul-060.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation.Ann SurgPMID 34597010无 PMCID2022-Jul-010.95The study is a randomized, Phase III oncology trial, but it lacks a drug-containing intervention (surgical comparison only) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).待处理
Functional Outcome of Laparoscopic-Assisted Resection Versus Open Resection of Rectal Cancer: A Secondary Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial.Dis Colon RectumPMID 34775413无 PMCID2022-Jul-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.Mod RheumatolPMID 34850095无 PMCID2022-Jul-010.90The record is excluded because it is a non-oncology study (rheumatoid arthritis) and lacks a primary/key secondary time-to-event efficacy endpoint as required.待处理
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials.Mod RheumatolPMID 34915576无 PMCID2022-Jul-010.98未发现恶性肿瘤人群证据。待处理
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.J Clin OncolPMID 35271306PMC92424092022-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.J Clin OncolPMID 35290101PMC92424062022-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).Am J CardiolPMID 35483979无 PMCID2022-Jul-010.98未发现恶性肿瘤人群证据。待处理
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.JAMA OncolPMID 35552364PMC91004602022-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial.JAMA OncolPMID 35616948PMC91366742022-Jul-010.95The study is a randomized Phase 3 trial in oncology (breast cancer) with original results, but it evaluates a non-drug intervention (radiotherapy positioning and fractionation) and the primary efficacy outcome is an acute toxicity endpoint (moist desquamation), not a time-to-event endpoint (like OS, PFS, DFS) requiring Kaplan-Meier or hazard ratio analysis.待处理
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.JAMA Netw OpenPMID 35834251PMC108812212022-Jul-010.98未发现恶性肿瘤人群证据。待处理
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.Eur J DermatolPMID 36301752无 PMCID2022-Jul-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.Br J OphthalmolPMID 34301613PMC92344032022-Jul0.98未发现恶性肿瘤人群证据。待处理
The perceived barriers and facilitators to implementation of early mobilisation within a multicentre, phase 3 randomised controlled trial: A qualitative process evaluation study.Aust Crit CarePMID 34321182无 PMCID2022-Jul0.98未发现恶性肿瘤人群证据。待处理
Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.BJU IntPMID 34657367无 PMCID2022-Jul0.93干预为非药物单独策略,未满足药物干预要求。待处理
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.Alzheimers DementPMID 34726348PMC95409002022-Jul0.98未发现恶性肿瘤人群证据。待处理